Routine

Venous thromboembolism & anticoagulation management

Haematology · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

VTE encompasses DVT and PE. Management centres on confirming the diagnosis, assessing severity and bleeding risk, and choosing anticoagulation, with DOACs first-line for most patients.

Red flags

  • Admit massive/high-risk PE, haemodynamic instability or high bleeding risk needing monitoring
  • Many low-risk PE and most DVT managed as outpatients (PESI/Hestia)
  • Refer: recurrent/unprovoked VTE, antiphospholipid syndrome, pregnancy, cancer-associated thrombosis, and significant bleeding on anticoagulation

Assessment

Investigations

  • Wells score then D-dimer (if low probability) or imaging
  • DVT: proximal leg compression ultrasound
  • PE: CTPA (or V/Q if contraindicated)
  • ECG (sinus tachycardia, S1Q3T3), troponin and echo for right-heart strain in PE
  • Baseline FBC, U&E, LFTs, clotting; consider cancer assessment in unprovoked VTE

Management

  • Lane 1 (most patients): a DOAC
  • Apixaban 10 mg BD for 7 days then 5 mg BD; or rivaroxaban 15 mg BD for 21 days then 20 mg OD; dabigatran/edoxaban need 5 days of LMWH lead-in
  • Lane 2: LMWH or warfarin (target INR 2-3) in antiphospholipid syndrome, severe renal impairment or pregnancy (LMWH)
  • Lane 3: thrombolysis (alteplase) for massive PE with haemodynamic instability;
  • IVC filter if anticoagulation contraindicated
  • Duration: 3 months provoked, consider long-term for unprovoked/recurrent/cancer

Disposition

Admit massive/high-risk PE, haemodynamic instability or high bleeding risk needing monitoring.

Complications & pitfalls

  • Fatal PE, right-heart failure, chronic thromboembolic pulmonary hypertension, post- thrombotic syndrome, recurrence
  • Anticoagulant bleeding including intracranial and GI
  • HIT with heparin
  • Reversal: idarucizumab for dabigatran; andexanet alfa or PCC for factor Xa inhibitors; vitamin K + PCC for warfarin

Exam pearls

  • A DOAC does not need a heparin lead-in only for apixaban and rivaroxaban; dabigatran and edoxaban require at least 5 days of parenteral LMWH first. Always check CrCl and weight before dosing and know your reversal agent.
  • Monitoring & follow-up: DOACs need no routine coagulation monitoring but check renal function and FBC at baseline and periodically (dose depends on CrCl/weight/age). Warfarin needs regular INR. Review at 3 months to decide duration and reassess bleeding vs recurrence risk. Counsel on adherence and signs of bleeding/recurrence.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.